Editorial content

November 2016 edition

​Our November edition is available to read now. The issue features companies and insight articles focused on nucleic-acid-based drugs, CNS and recent M&A activity in the pharma and biotech industry.

Go to the profile of Raveena Bhambra
Nov 01, 2016
2
0
Upvote 2 Comment

Read the newly released November edition of BioPharma Dealmakers.

Browse through the companies looking for partnerships in CNS and nucleic-acid-based drugs.

AMRI

Arcturus Therapeutics

Astex Pharmaceuticals

BioPact

Cognition Therapeutics

Dicerna

Exicure

Intellipharmaceutics

MeiraGTx

Replicor

SpineThera

Voyager Therapeutics


Aligning to these company profiles are our November in-depth feature articles that explore focus on the dealmaking activity within CNS, Pharma M&As and Nucleic-acid-based drugs.

Dealmaking and differentiation in migraine’s big new market

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Publishing Group

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 12 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.